| 1 |
33764811 | Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin. | 2022 Feb |
1 |
| 2 |
33487222 | Retraction notice to 'The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells' [EBioMedicine 35 (2018) 204-221]. | 2021 Jan |
2 |
| 3 |
33747222 | Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer. | 2021 May |
4 |
| 4 |
33747282 | Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients. | 2021 |
2 |
| 5 |
34353292 | RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. | 2021 Aug 5 |
1 |
| 6 |
34532603 | A newly established monoclonal antibody against ERCC1 detects major isoforms of ERCC1 in gastric cancer. | 2021 Aug 31 |
3 |
| 7 |
34962119 | Engineering Supramolecular Nanomedicine for Targeted Near Infrared-triggered Mitochondrial Dysfunction to Potentiate Cisplatin for Efficient Chemophototherapy. | 2021 Dec 28 |
1 |
| 8 |
32028591 | TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy. | 2020 Feb 3 |
1 |
| 9 |
32173978 | Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort. | 2020 Oct |
1 |
| 10 |
32437713 | Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells. | 2020 Aug 15 |
1 |
| 11 |
32478168 | Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149. | 2020 Jun 26 |
10 |
| 12 |
32582340 | The prognostic value of excision repair cross-complementing Group 1 expression in nasopharyngeal cancer patients. | 2020 |
2 |
| 13 |
32739873 | Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance. | 2020 Aug |
3 |
| 14 |
32922493 | A Preliminary Study of NER and MMR Pathways Involved in Chemotherapy Response in Bladder Transitional Cell Carcinoma: Impact on progression-free survival. | 2020 Winter |
1 |
| 15 |
33133187 | Corrigendum to "UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells". | 2020 |
1 |
| 16 |
33154302 | Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. | 2020 Oct-Dec |
4 |
| 17 |
33164868 | Sclareol ameliorated ERCC1-mediated cisplatin resistance in A549 human lung adenocarcinoma cells and a murine xenograft tumor model by suppressing AKT-GSK3β-AP1/Snail and JNK-AP1 pathways. | 2020 Dec 1 |
1 |
| 18 |
33266377 | Clinical Perspectives of ERCC1 in Bladder Cancer. | 2020 Nov 22 |
1 |
| 19 |
30066234 | Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine. | 2019 Jul |
1 |
| 20 |
30535472 | miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin. | 2019 Feb |
1 |
| 21 |
30538112 | Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer. | 2019 Apr 15 |
1 |
| 22 |
30550405 | Combination of ω-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study. | 2019 Jun |
4 |
| 23 |
30584903 | Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment. | 2019 Apr 5 |
5 |
| 24 |
30668408 | Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways. | 2019 Feb |
1 |
| 25 |
30728154 | The "Guardian of the Genome"-An Old Key to Unlock the ERCC1 Issue. | 2019 Apr 15 |
1 |
| 26 |
31083486 | Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. | 2019 May 10 |
3 |
| 27 |
31152437 | Chemoresistance in gastric cancer is attributed to the overexpression of excision repair cross-complementing 1 (ERCC1) caused by microRNA-122 dysregulation. | 2019 Dec |
5 |
| 28 |
31586226 | Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1. | 2019 Dec |
2 |
| 29 |
31772670 | CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. | 2019 |
1 |
| 30 |
28918673 | Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins. | 2018 Nov |
1 |
| 31 |
29177570 | Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. | 2018 May |
1 |
| 32 |
29315773 | miR-451 selectively increases sensitivity to cisplatin in ERCC1-high non-small cell lung cancer cells. | 2018 Jan 6 |
3 |
| 33 |
29330293 | Differential Regulation of LET-7 by LIN28B Isoform-Specific Functions. | 2018 Mar |
1 |
| 34 |
29399358 | Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers. | 2018 Feb |
1 |
| 35 |
29439312 | Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy. | 2018 |
3 |
| 36 |
29482102 | A novel antibody-based approach to detect the functional ERCC1-202 isoform. | 2018 Apr |
1 |
| 37 |
29578165 | Predictive value of excision repair cross-complementation group 1 protein in locoregionally advanced nasopharyngeal carcinomas receiving cisplatin-based concurrent chemoradiotherapy. | 2018 |
5 |
| 38 |
29620255 | Different splicing isoforms of ERCC1 affect the expression of its overlapping genes CD3EAP and PPP1R13L, and indicate a potential application in non-small cell lung cancer treatment. | 2018 Jun |
2 |
| 39 |
29872959 | Role of Telomeric TRF2 in Orosphere Formation and CSC Phenotype Maintenance Through Efficient DNA Repair Pathway and its Correlation with Recurrence in OSCC. | 2018 Dec |
1 |
| 40 |
29905882 | ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer. | 2018 Jun 15 |
2 |
| 41 |
29980176 | The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients. | 2018 Jul 6 |
2 |
| 42 |
30066933 | Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. | 2018 Oct |
1 |
| 43 |
30146342 | The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. | 2018 Sep |
2 |
| 44 |
30279363 | Gap Junction Intercellular Communication Positively Regulates Cisplatin Toxicity by Inducing DNA Damage through Bystander Signaling. | 2018 Oct 2 |
4 |
| 45 |
30400270 | Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells. | 2018 Nov 3 |
3 |
| 46 |
30563166 | Demethoxycurcumin-Loaded Chitosan Nanoparticle Downregulates DNA Repair Pathway to Improve Cisplatin-Induced Apoptosis in Non-Small Cell Lung Cancer. | 2018 Dec 5 |
5 |
| 47 |
26918827 | XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. | 2017 Mar 7 |
3 |
| 48 |
27737534 | ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. | 2017 Jul |
2 |
| 49 |
27893326 | Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). | 2017 Feb |
2 |
| 50 |
28260069 | Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance. | 2017 Apr |
3 |